Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the comprehensive WuXi AppTec pharmacodynamics service platform. Other interesting topics covered in this issue include our platform for STING pathway-related assays and an update on c-Met-related in vivo models.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
Translational Oncology
(1)  Overview of our facility

(2)  Service introduction and relevant case studies


Immuno-Oncology
(1)  STING background
  • STING signaling pathway
  • Summary of current industrial pipelines on STING agonists

(2)  In vitro cellular functional assay for STING pathway
  • STING agonist stimulation on human PBMCs and THP1 cells, using production of IFN-β as a readout

(3)  Cytokine analysis of B16F10 syngeneic model post STING agonist treatment
  • IL-6 and TNF-α level in plasma
  • IL-6, TNF-α, IFN-γ, MCP-1, IL-12, and IFN-β level in tumor

(4)  In vivo anti-tumor efficacy study of STING agonist in B16F10, CT26, and 4T1 syngeneic models

(5)  Immune cell activation analysis in TILs and spleen in B16F10 syngeneic model post STING agonist treatment

Targeted Oncology
(1)  c-Met background
  • c-Met biology
  • Summary of c-Met inhibitors

(2)  c-Met-related CDX models
  • 9 CDX models with aberrant c-Met activation, covering gastric, liver, glioblastoma, lung, and pancreatic cancer types
  • MKN45 gastric cancer CDX model, validated with BMS777607 and LY2801653
  • Hs746T gastric cancer CDX model, validated with Tepotinib, INCB28060, and Cabozantinib
  • MHCC97H HCC and EBC-1 lung cancer CDX models, validated with Tepotinib
  • U87MG glioblastoma CDX model, validated with Crizotinib
  • NCI-H820 lung cancer CDX model, validated with INCB28060 and Cabozantinib

(3)  c-Met-related PDX models
  • c-Met expression level across PDX models
  • LU-01-1375 lung cancer PDX model carrying MET exon 14 skipping mutation, validated with Tepotinib, INCB28060, Savolitinib, Crizotinib, and Cabozantinib
  • 3 liver cancer PDX models, validated with INCB28060, Foretinib or other c-Met inhibitors
  • 3 lung cancer PDX models, validated with INCB28060 or Crizotinib
  • LU-01-0751 lung cancer PDX model carrying clinically acquired INCB28060-resistant MET mutation, validated with INCB28060 and Cabozantinib


We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

 
Best regards,
WuXi AppTec OncoWuXi Team